X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13763) 13763
Newsletter (113) 113
Newspaper Article (40) 40
Magazine Article (27) 27
Transcript (20) 20
Book / eBook (12) 12
Book Review (4) 4
Book Chapter (3) 3
Conference Proceeding (2) 2
Dissertation (1) 1
Publication (1) 1
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12871) 12871
female (8096) 8096
oncology (6766) 6766
middle aged (5525) 5525
male (5121) 5121
aged (4846) 4846
breast neoplasms - drug therapy (4485) 4485
cancer (4269) 4269
adult (3873) 3873
breast cancer (3743) 3743
chemotherapy (3614) 3614
antineoplastic agents, hormonal - therapeutic use (3419) 3419
treatment outcome (3359) 3359
antineoplastic combined chemotherapy protocols - therapeutic use (2995) 2995
antineoplastic agents, hormonal - administration & dosage (2878) 2878
antineoplastic agents - therapeutic use (2720) 2720
care and treatment (2629) 2629
breast neoplasms - pathology (2318) 2318
prostatic neoplasms - drug therapy (2131) 2131
animals (2101) 2101
medicine & public health (2098) 2098
aged, 80 and over (1889) 1889
prostate cancer (1864) 1864
therapy (1809) 1809
research (1745) 1745
tamoxifen (1717) 1717
pharmacology & pharmacy (1652) 1652
health aspects (1470) 1470
antineoplastic agents, hormonal - adverse effects (1459) 1459
antineoplastic agents - administration & dosage (1445) 1445
drug therapy (1421) 1421
chemotherapy, adjuvant (1400) 1400
antineoplastic agents (1399) 1399
metastasis (1397) 1397
prognosis (1315) 1315
antineoplastic agents - adverse effects (1308) 1308
drug administration schedule (1308) 1308
disease-free survival (1303) 1303
neoplasm staging (1212) 1212
antimitotic agents (1210) 1210
analysis (1198) 1198
antineoplastic combined chemotherapy protocols - adverse effects (1158) 1158
survival (1091) 1091
carcinoma (1082) 1082
tumors (1067) 1067
tamoxifen - administration & dosage (1056) 1056
urology & nephrology (1041) 1041
tamoxifen - therapeutic use (1035) 1035
retrospective studies (1034) 1034
hematology, oncology and palliative medicine (1014) 1014
postmenopausal women (1013) 1013
prostatic neoplasms - pathology (1013) 1013
clinical trials (1009) 1009
docetaxel (988) 988
risk factors (979) 979
antineoplastic agents - pharmacology (972) 972
women (972) 972
survival analysis (968) 968
combined modality therapy (942) 942
dose-response relationship, drug (941) 941
neoplasm metastasis (941) 941
breast neoplasms - metabolism (936) 936
neoplasms - drug therapy (932) 932
follow-up studies (924) 924
time factors (902) 902
antineoplastic agents, hormonal - pharmacology (860) 860
expression (856) 856
breast neoplasms - mortality (842) 842
cancer therapies (823) 823
antineoplastic combined chemotherapy protocols - administration & dosage (819) 819
trial (797) 797
mice (777) 777
obstetrics & gynecology (777) 777
survival rate (770) 770
dosage and administration (753) 753
clinical trials as topic (752) 752
estrogen (747) 747
prospective studies (745) 745
surgery (715) 715
cell line, tumor (701) 701
disease progression (697) 697
breast-cancer (694) 694
endocrine therapy (693) 693
drug resistance, neoplasm (692) 692
apoptosis (690) 690
radiotherapy (665) 665
quality of life (660) 660
oncology, experimental (652) 652
prostate-specific antigen - blood (639) 639
paclitaxel (637) 637
randomized-trial (633) 633
trastuzumab (627) 627
randomized controlled trials as topic (625) 625
cancer research (619) 619
internal medicine (619) 619
endocrinology & metabolism (618) 618
pharmacology/toxicology (618) 618
taxoids - administration & dosage (610) 610
androgen antagonists - therapeutic use (609) 609
patients (608) 608
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13412) 13412
Japanese (248) 248
German (111) 111
French (95) 95
Russian (65) 65
Italian (42) 42
Spanish (32) 32
Chinese (30) 30
Hungarian (23) 23
Polish (16) 16
Danish (9) 9
Portuguese (7) 7
Czech (6) 6
Norwegian (5) 5
Dutch (4) 4
Swedish (4) 4
Romanian (3) 3
Bulgarian (2) 2
Finnish (2) 2
Serbian (2) 2
Ukrainian (2) 2
Croatian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research, ISSN 1557-3265, 2016, Volume 22, Issue 11, pp. 2650 - 2658
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 12/2011, Volume 71, Issue 24, pp. 7597 - 7607
Insulin-like growth factor (IGF) signaling has been implicated in the resistance to hormonal therapy in breast cancer... 
INSULIN-RECEPTOR ISOFORM | TAMOXIFEN WITHDRAWAL | ACTIVATION | THERAPY | EXEMESTANE | ONCOLOGY | TRANSCRIPTION | RESISTANCE | POSTMENOPAUSAL WOMEN | EXPRESSION | GROWTH-FACTOR-I | Receptor, IGF Type 1 - metabolism | Triazoles - administration & dosage | Estradiol - analogs & derivatives | Receptor, IGF Type 1 - antagonists & inhibitors | Nitriles - pharmacology | Oligonucleotide Array Sequence Analysis | Humans | Gene Expression Profiling | Mammary Neoplasms, Experimental - metabolism | Tamoxifen - administration & dosage | Mammary Neoplasms, Experimental - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Receptor, Insulin - genetics | Female | Estrogens - metabolism | Estradiol - pharmacology | Mammary Neoplasms, Experimental - drug therapy | Pyrazoles - pharmacology | Triazines - pharmacology | Antineoplastic Agents, Hormonal - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Estradiol - administration & dosage | Receptor, Insulin - antagonists & inhibitors | Receptor, IGF Type 1 - genetics | Blotting, Western | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | Tamoxifen - pharmacology | Cell Line, Tumor | Tamoxifen - analogs & derivatives | Receptor, Insulin - metabolism | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C
Journal Article
Molecular cancer, ISSN 1476-4598, 2013, Volume 12, Issue 1, pp. 9 - 9
Background: Estrogen receptor-alpha (ER alpha)-negative breast cancer is clinically aggressive and normally does not respond to conventional estrogen... 
Breast cancer | Epigenetic | Tamoxifen | ERα | Genistein | CELLS | HISTONE DEACETYLASE INHIBITOR | METHYLATION | ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | TRICHOSTATIN-A | IN-VITRO | ONCOLOGY | GROWTH | GENES | EXPRESSION | ER alpha | Gene Expression - drug effects | Humans | Tamoxifen - administration & dosage | DNA (Cytosine-5-)-Methyltransferases - metabolism | Anticarcinogenic Agents - administration & dosage | Estrogen Receptor alpha - metabolism | Female | Genistein - administration & dosage | Epigenesis, Genetic - drug effects | Anticarcinogenic Agents - pharmacology | Hydroxamic Acids - pharmacology | Estradiol - pharmacology | Cell Survival - drug effects | Promoter Regions, Genetic | Antineoplastic Agents, Hormonal - pharmacology | DNA (Cytosine-5-)-Methyltransferase 1 | Antineoplastic Agents, Hormonal - administration & dosage | Azacitidine - analogs & derivatives | Mice, Transgenic | Breast Neoplasms - drug therapy | Breast Neoplasms - prevention & control | Drug Synergism | Xenograft Model Antitumor Assays | Azacitidine - pharmacology | Animals | Estrogen Receptor alpha - genetics | Tumor Burden - drug effects | Breast Neoplasms - pathology | Mice, Nude | Genistein - pharmacology | Tamoxifen - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Mice | Histones - metabolism | Proliferating Cell Nuclear Antigen - metabolism | Drug Resistance, Neoplasm - drug effects | Histone Deacetylase 1 - metabolism
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
... for men whose disease had not spread. This century, new agents began to show valuable activity in relapsed, metastatic, castrate-refractory prostate cancer—including... 
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies
Journal Article
Journal Article